Oncogene-induced senescence: The bright and dark side of the response

Current Opinion in Cell Biology

Volumn 22, Issue 6, 2010, Pages 816-827

  Gorgoulis, Vassilis G ^a   Halazonetis, Thanos D ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; AUTOPHAGY; BIOENERGY; CELL CYCLE REGULATION; CELL PROLIFERATION; DNA DAMAGE; FIBROBLAST; HUMAN; NONHUMAN; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SENESCENCE; TUMOR SUPPRESSOR GENE;

ANIMALS; AUTOPHAGY; CELL AGING; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; NEOPLASMS; ONCOGENES; PHENOTYPE; SIGNAL TRANSDUCTION;

EID: 78649629320     PISSN: 09550674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ceb.2010.07.013     Document Type: Review

References (126)

1. Campisi J., d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007, 8:729-740.
2. Beauséjour C.M., Krtolica A., Galimi F., Narita M., Lowe S.W., Yaswen P., Campisi J. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J 2003, 22:4212-4222.
3. Sage J., Miller A.L., Perez-Mancera P.A., Wysocki J.M., Jacks T. Acute mutation of retinoblastoma binding defective SV40 T antigens in serum deprived and senescent human fibroblasts. Oncogene 2003, 8:1887-1893.
4. Hayflick L., Moorhead P.S. The serial cultivation of human diploid cell strains. Exp Cell Res 1961, 25:585-621.
5. Newbold R.F., Overell R.W. Fibroblast immortality is a prerequisitive for transformation by EJ c-Ha-ras oncogene. Nature 1983, 304:648-651.
6. Serrano M., Lin A.W., McCurrach M.E., Beach D., Lowe S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997, 88:593-602.
7. Wei S., Wei W., Sedivy J.M. Expression of catalytically active telomerase does not prevent premature senescence caused by overexpression of oncogenic ha-Ras in normal human fibroblasts. Cancer Res 1999, 59:1539-1543.
8. Lowe S.W., Cepero E., Evan G. Intrinsic tumor suppression. Nature 2004, 432:307-315.
9. Shay J.W., Roninson I.B. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 2004, 23:2919-2933.
10. Benanti J., Galloway D. Normal human fibroblasts are resistant to RAS-induced senescence. Mol Cell Biol 2004, 24:2842-2852.
11. Sherr C.J., Depinho R.A. Cellular senescence: mitotic clock or cultural shock?. Cell 2000, 102:407-410.
12. Collado M., Gil J., Efeyan A., Guerra C., Schuhmacher A.J., Barradas M., Benguria A., Zaballos A., Flores J.M., Barbacid M., Serrano M. Tumor biology: senescence in premalignant tumours. Nature 2005, 436:642.
13. Morton J.P., Timpson P., Karim S.A., Ridqway R.A., Athineos D., Doyle B., Jamieson N.B., Oien K.A., Lowy A.M., Brunton V.G., et al. Mutant but not knockout p53 drives metastatic pancreatic cancer. Proc Natl Acad Sci U S A 2010, 107:246-251.
14. Harris T.J., McCormik F. The molecular pathology of cancer. Nat Rev Clin Oncol 2010, 7:251-265.
15. Braig M., lee S., Loddenkemper C., Rudolph C., Peters A.H.F.M., Schlegelberger B., Stein H., Dörken B., Jenuwein T., Schmitt C.A. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 2005, 436:660-665.
16. Michaloglou C., Vredeveld L.C., Soengas M.S., Denoyelle C., Kuilman T., van der Horst C.M., Majoor D.M., Shay J.W., Mooi W.J., Peeper D.S. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005, 436:720-724.
17. Dankort D., Filenova E., Collado M., Serrano M., Jones K., McMahon M. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev 2007, 21:379-384.
18. Goel V.K., Ibrahim N., Jiang G., Singhal M., Fee S., Flotte T., Westmoreland S., Haluska F.S., Hinds P.W., Haluska F.G. Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice. Oncogene 2009, 28:2289-2298.
19. Davies H., Bignel G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
20. Yang N.C., Hu M.L. The limitations and validities of senescence associated-beta-galactosidase activity as an aging marker for human foreskin fibroblast Hs68 cells. Exp Gerontol 2005, 40:813-819.
21. Collado M., Serrano M. The power and the promise of oncogene-induced senescence markers. Nat Rev Cancer 2006, 6:472-476.
22. Nielsen S.J., Schneider R., Bauer U.M., Bannister A.J., Morrison A., O'Carroll D., Firestein R., Cleary M., Jenuwein T., Herrera R.E., Kouzarides T. Rb targets histone H3 methylation and HP1 to promoters. Nature 2001, 412:561-565.
23. Narita M., Nunez S., Heard E., Lin A.W., Hearn S.A., Spector D.L., Hannon G.J., Lowe S.W. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 2003, 113:703-716.
24. Wolyniec K., Wotton S., Kilbey A., Jenkins A., Terry A., Peters G., Stocking C., Cameron E., Neil J.C. RUNX1 and its fusion oncoprotein derivative, RUNX1-ETO, induce senescence-like growth arrest independently of replicative stress. Oncogene 2009, 28:2502-2512.
25. Sarkisian C.J., Keister B.A., Stairs D.B., Boxer R.B., Moody S.E., Chodosh L.A. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol 2007, 9:493-505.
26. Mo L., Zheng X., Huang H.Y., Shapiro E., Lepor H., Cordon-Cardo C., Sun T.T., Wu X.R. Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. J Clin Invest 2007, 117:314-325.
27. Murphy D.J., Junttila M.R., Pouvet L., Karnezis A., Shchors K., Bui D.A., Brown-Swigart L., Johnson L., Evan G.I. Distinct thresholds govern Myc's biological output in vivo. Cancer Cell 2008, 14:447-457.
28. Chen Z., Trotman L.C., Shaffer D., Lin H.K., Dotan Z.A., Niki M., Koutcher J.A., Scher H.I., Ludwig T., Gerald W., et al. Crucial role of the p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005, 436:725-730.
29. Young A.P., Schlisio S., Minamishima Y.A., Zhang Q., Lin L., Grisanzio C., Signoretti S., Kaelin W.G. VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nat Cell Biol 2008, 10:361-369.
30. Chalhoub N., Baker S.J. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol 2009, 4:127-150.
31. Kaelin W.G. The von Hippel-Lindau tumor suppressor protein: O2 sensing and cancer. Nat Rev Cancer 2008, 8:865-873.
32. Lazzerini D.E., Atwooll C., Pasini D., Helin K. Deregulated E2F activity induces hyperplasia and senescence-like features in the mouse pituitary gland. Mol Cell Biol 2005, 25:2660-2672.
33. Shamma A., Tagekami Y., Miki T., Kitajima S., Noda M., Obara T., Okamoto T., Takahashi C. Rb regulates DNA damage response and cellular senescence through E2F-depedent suppression of N-ras isoprenylation. Cancer Cell 2009, 15:255-269.
34. Bartkova J., Rezaei N., Liontos M., Karakaidos P., Kletsas D., Issaeva N., Vassiliou L.V., Kolettas E., Niforou K., Zoumpourlis V.C., et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006, 444:633-637.
35. Fujita K., Mondal A.M., Horikawa I., Nguyen G.H., Kumamoto K., Sohn J.J., Bowman E.D., Mathe E.A., Schetter A.J., Pine S.R., et al. p53 isoforms, Δ133p53 and p53β, are endogenous regulators of replicative cellular senescence. Nat Cell Biol 2009, 11:1135-1142.
36. Kuilman T., Michaloglou C., Vredeveld L.C., Douma S., van Doorn R., Desmet C.J., Aarden L.A., Mooi W.J., Peeper D.S. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 2008, 133:1019-1031.
37. Acosta J.C., O'Loghlen A., Banito A., Guijarro M.V., Augert A., Raguz S., Fumagalli M., Da Costa M., Brown C., Popov N., et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 2008, 133:1006-1018.
38. Halazonetis T.D., Gorgoulis V.G., Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008, 319:1352-1355.
39. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 2005, 120:513-522.
40. Polager S., Ginsberg D. p53 and E2F: partners in life and death. Nat Rev Cancer 2009, 9:738-748.
41. Zindy F., Williams R.T., Baudino T.A., Rehg J.E., Skapek S.X., Cleveland J.L., Roussel M.F., Sherr C.J. Arf tumor suppressor promoter monitors latent oncogenic signals in vivo. Proc Natl Acad Sci U S A 2003, 100:15930-15935.
42. Di Micco R., Fumagalli M., Cicalese A., Piccinin S., Gasparini P., Luise C., Schurra C., Garre' M., Nuciforo P.G., Bensimon A., et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006, 444:638-642.
43. Mallette F.A., Gaumont-Leclerc M.F., Ferbeyre G. The DNA damage signalling pathway is critical mediator of oncogene-induced senescence. Genes Dev 2007, 21:43-48.
44. Liontos M., Koutsami M., Sideridou M., Evangelou K., Kletsas D., Levy B., Kotsinas A., Nahum O., Zoumpourlis V., Kouloukousa M., et al. Deregulated overexpression of hCdt1 and hCdc6 promotes malignant behavior. Cancer Res 2007, 67:10899-10909.
45. Liontos M., Niforou K., Velimezi G., Vougas K., Evangelou K., Apostolopoulou K., Vrtel R., Damalas A., Kontovazenitis P., Kotsinas A., et al. Modulation of the E2F1-driven cancer cell fate by the DNA damage response machinery and potential novel E2F1 targets in osteosarcomas. Am J Pathol 2009, 175:376-391.
46. Chao C., Herr D., Chun J., Xu Y. Ser18 and 23 phosphorylation is required for p53-dependent apoptosis and tumor suppression. EMBO J 2006, 25:2615-2622.
47. Westphal C.H., Rowan S., Schmaltz C., Elson A., Fisher D.E., Leder P. Atm and p53 cooperate in apoptosis and suppression of tumorigenesis, but not in resistance to acute radiation toxicity. Nat Genet 1997, 16:397-401.
48. Moore L., Venkatachalam S., Vogel H., Watt J.C., Wu C.L., Steinman H., Jones S.N., Donehower L.A. Cooperativity of p19ARF, Mdm2 and p53 in murine tumorigenesis. Oncogene 2003, 2:7831-7837.
49. Weber J.D., Jeffers J.R., Rehg J.E., Randle D.H., Lozano G., Roussel M.F., Sherr C.J., Zambetti G.P. p53-independent functions of the p14(ARF) tumor suppressor. Genes Dev 2000, 14:2358-2365.
50. Damalas A, Velimezi G, Kalitzakis A, Liontos M, Papavassiliou AG, Gorgoulis V, Angelidis C: Loss of p14ARF confers resistance to heat shock and oxidative stress mediated cell death by upregulating β-catenin. Int J Cancer 2010, in press [Epub ahead of print].
51. Gabai V.L., Yaglom J.A., Waldman T., Sherman M.Y. Heat shock protein Hsp72 controls oncogene-induced senescence pathways in cancer cells. Mol Cell Biol 2009, 29:559-569.
52. Gorgoulis V.G., Vassiliou L.V.F., Karakaidos P., Zacharatos P., Kotsinas A., Liloglou T., Venere M., DiTullio R.A., Kastrinakis N.G., Levy B., et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005, 434:904-913.
53. Bartkova J., Zuzana Hořejš, Koed K., Krämer A., Tort F., Zieger K., Guldberg P., Sehested M., Nesland J.M., Lukas C., et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434:864-870.
54. Efeyan A., Murga M., Martinez-Pastor B., Ortega-Molina A., Soria R., Collado M., Fernandez-Capetillo O., Serrano M. Limited role of murine ATM in oncogene-induced senescence and p53-dependent tumor suppression. PLoS ONE 2009, 4:e5475.
55. Wei H., Hemmer R.M., Sedivy J.M. Role of p14(ARF) in replicative and induced senescence of human fibroblasts. Mol Cell Biol 2001, 21:6748-6757.
56. Evan G.I., d'Adda di Fagagna Cellular senescence: hot or what?. Curr Opin Genet Dev 2009, 19:25-31.
57. Steeramaneni R., Chaudhry A., McMahon M., Sherr C.J., Inoue K. Ras-Raf-arf signaling critically depends on the Dmp1 transcription factor. Mol Cell Biol 2005, 25:220-232.
58. Agger K., Cloos P.A.C., Rudkjær L., Williams K., Andersen G., Christensen J., Helin K. The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene and stress-induced senescence. Genes Dev 2009, 23:1171-1176.
59. Barradas M., Anderton E., Acosta J.C., Li S.D., Banito A., Rodriguez-Niedenfür M., Maertens G., Banck M., Zhou M.M., Walsh M.J., et al. Histone demethylase JMJD3contributes to epigenetic control of INK4a/ARF by oncogenic RAS. Genes Dev 2009, 23:1177-1182.
60. Orjalo A.V., Bhaumik D., Gengler B.K., Scott G.K., Campisi J. Cell surface-bound IL-1alpha is an upstream regulator of the senescence-associated IL-6/IL-8 cytokine network. Proc Natl Acad Sci U S A 2009, 106:17031-17036.
61. Rodier F., Coppé J.P., Patil C.K., Hoeijmakers W.A.M., Munoz D.P., Raza S.R., Freund A., Campeau E., Davalos A.R., Campisi J. Persistent DNA damage signaling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol 2009, 11:973-979.
62. Kwong J., Hong L., Liao R., Deng Q., Han J., Sun P. p38alpha and p38gamma mediate oncogenic ras-induced senescence through differential mechanisms. J Biol Chem 2009, 284:11237-11246.
63. Sun P., Yoshizuka N., New L., Moser B.A., Li Y., Liao R., Xie C., Chen J., Deng Q., Yamout M., et al. PRAK is essential for ras-induced senescence and tumor suppression. Cell 2007, 128:295-308.
64. Mallette F.A., Calabrese V., Ilangumaran S., Ferbeyre G. SOCS1, a novel interaction partner of p53 controlling oncogene-induced senescence. Aging (Albany NY) 2010, June 26 [Epub ahead of print].
65. Batsi C., Markopoulou S., Vartholomatos G., Georgiou I., Kanavaros P., Gorgoulis V.G., Marcu K.B., Kolettas E. Chronic NF-kB activation delays RasV12-induced premature senescence of human fibroblasts by suppressing the DNA damage checkpoint response. Mech Ageing Dev 2009, 130:409-419.
66. Courtois-Cox S., Genther Williams S.M., Reczek E.E., Johnson B.W., McGillicuddy L.T., Johannessen C.M., Hollstein P.E., MacCollin M., Cichowski K. A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 2006, 10:459-472.
67. Wajapeyee N., Serra R.W., Zhu X., Mahalingam M., Green M.R. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 2008, 132:363-374.
68. Scurr L.L., Pupo G.M., Becker T.M., Lai K., Schrama D., Haferkamp S., Irvine M., Scolyer R.A., Mann G.J., Becker J.C., et al. IGFBP7 is not required for B-RAF-induced melanocyte senescence. Cell 2010, 141:717-727.
69. Coppé J.P., Patil C.K., Rodier F., Sun Y., Muñoz D.P., Goldstein J., Nelson P.S., Desprez P.Y., Campisi J. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 2008, 6:2853-2868.
70. Kuilman T., Peeper D.S. Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer 2009, 9:81-94.
71. Kortlever R.M., Higgins P.J., Bernards R. Plasminogen activator inhibitor-1 is critical downstream target of p53 in the activation of replicative senescence. Nat Cell Biol 2006, 8:877-884.
72. Reimann M., Lee S., Loddenkemper C., Dörr J.R., Tabor V., Aichele P., Stein H., Dörken B., Jenuwein T., Schmitt C.A. Tumor stroma-derived TGF-β limits Myc-driven lymphomagenesis via Suv39h1-depedent senescence. Cancer Cell 2010, 17:262-272.
73. Krtolica A., Parrinello S., Lockett S., Desprez P.Y., Campisi J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci U S A 2001, 98:12072-12077.
74. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
75. Parinello S., Coppe J.P., Krtolica A., Campisi J. Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter cell differentiation. J Cell Sci 2005, 118:485-496.
76. Coppé J.P., Kauser K., Campisi J., Beausejour C.M. Secretion of vascular endothelial growth factor by primary human fibroblasts at senescence. J Biol Chem 2006, 281:29568-29574.
77. Herbig U., Ferreira M., Condel L., Carey D., Sedivy J.M. Cellular senescence in aging primates. Science 2006, 311:1257.
78. Dollé M.E., Snyder W.K., Dunson D.B., Viig J. Mutational fingerprints aging. Nucleic Acids Res 2002, 30:545-549.
79. Jonason A.S., Kunala S., Price G.J., Restifo R.J., Spinelli H.M., Persing J.A., Leffell D.J., Tarone R.E., Brash D.E. Frequent clones of p53-mutated keratinocytes in normal human skin. Proc Natl Acad Sci U S A 1996, 93:14025-14029.
80. Jackson S.P., Bartek J. The DNA-damage response in human biology and disease. Nature 2009, 461:1071-1078.
81. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
82. Moiseeva O., Bourdeau V., Roux A., Deschenes-Simard X., Ferbeyre G. Mitochondrial dysfunction contributes to oncogene-induced senescence. Mol Cell Biol 2009, 16:4495-4507.
83. Wilkinson S., Ryan K.M. Autophagy: an adaptable modifier of tumorigenesis. Curr Opin Genet Dev 2009, 20:57-64.
84. Young A.R., Narita M., Ferreira M., Kirschner K., Sadaie M., Darot J.F., Tavaré S., Arakawa S., Shimizu S., Watt F.M. Autophagy mediates the mitotic senescence transition. Genes Dev 2009, 23:798-803.
85. Qu X., Yu J., Bhagat G., Furuya N., Hibshoosh H., Troxel A., Rosen J., Eskelinen E.L., Mizushima N., Ohsumi Y., et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest 2003, 112:1809-1820.
86. Steeves M.A., Dorsey F.C., Cleveland J.L. Targeting the autophagy pathway for cancer chemoprevention. Curr Opin Cell Biol 2009, 22:251-271.
87. Robertson R.S., Kussick S.J., Vallieres E., Chen S.Y., Wu D.Y. Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. Cancer Res 2005, 65:2795-2803.
88. te Poele R.H., Okorokov A.L., Jardine L., Cummings J., Joel S.P. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 2002, 62:1876-1883.
89. Xue W., Zender L., Miething C., Dickins R.A., Hernando E., Krizhanovsky V., Cordon-Cardo C., Lowe S.C. Senescence ant tumor clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007, 445:656-660.
90. Ventura A., Kirsch D.G., McLaughlin M.E., Tuveson D.A., Grimm J., Lintault L., Newman J., Reczek E.E., Weissleder R., Jacks T. Restoration of p53 function leads to tumor regression in vivo. Nature 2007, 445:661-665.
91. Brown C.J., Lain S., Verma C.S., Fersht A.R., Lane D.P. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 2009, 9:862-873.
92. Nakyama K.I., Nakayama K. Regulation of the cell cycle by SCF-type ubiquitin ligases. Semin Cell Dev Biol 2005, 16:323-333.
93. Lin H.K., Chen Z., Whang G., Nardell C., Lee S.W., Chan C.H., Yang W.L., Wang J., Egia A., Nakayama K.I., et al. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 2010, 464:374-379.
94. Campaner S., Doni M., Hydbring P., Verrecchia A., Bianchi L., Sardella D., Schleker T., Perna D., Tronnersjö S., Murga M., et al. Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat Cell Biol 2010, 12:54-60.
95. Hydbring P., Bahram F., Su Y., Tronnersjö S., Högstrand K., von der Lehr N., Sharifi H.R., Lilischkis R., Hein N., Wu S., et al. Phosphorylation by Cdk2 is required for myc to repress Ras-induced senescence in cotransformation. Proc Natl Acad Sci U S A 2010, 107:58-63.
96. Koutsami M., Velimezi G., Kotsinas A., Evangelou K., Papavassiliou A.G., Kittas C., Gorgoulis V.G. Is exclusive Skp2 targeting always beneficial in cancer therapy?. Blood 2008, 112:4777-4779.
97. Ansieau S., Bastid J., Doreau A., Morel A.P., Bouchet B.P., Thomas C., Fauvet F., Puisieux I., Doglioni C., Piccinin S., et al. Induction of EMT by Twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell 2008, 14:79-89.
98. Lee J.M., Dedhar S., Kalluri R., Thompson E.W. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006, 172:973-981.
99. Cutroneo K.R., White S.L., Chiu J.F., Ehrlich H.P. Tissue fibrosis and carcinogenesis: divergent or successive pathways dictate multiple molecular therapeutic targets for oligo decoy therapies. J Cell Biochem 2006, 97:1161-1174.
100. Tazawa H., Tsuchiya N., Izumiya M., Nakagama H. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci U S A 2007, 104:15472-15477.
101. Dimri G.P., Lee X., Basile G., Acosta M., Scott G., Roskelley C., Medrano E.E., Linskens M., Rubeli I., Pereira-Smith O., et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995, 92:9363-9367.
102. Johnson T.M., Meade K., Pathak N., Marques M.R., Attardi L.D. Knockin mice expressing a chimeric p53 protein reveal mechanistic differences in how p53 triggers apoptosis and senescence. Proc Natl Acad Sci U S A 2008, 105:1215-1220.
103. Xu M., Yu Q., Subrahmanyam R., Difilippantinio M.J., Ried T., Sen J.M. β-Catenin expression results in p53-independent DNA damage and oncogene-induced senescence in prelyphomagenic thymocytes in vivo. Mol Cell Biol 2007, 28:1713-1723.
104. Leikam C., Hufnagel A., Schartl M., Meierjohann S. Oncogene activation in melanocytes links reactive oxygen to multinucleated phenotype and senescence. Oncogene 2008, 27:7070-7082.
105. Debidda M., Williams D.A., Zheng Y. Rac1 GTPase regulates cell genomic instability and senescence. J Biol Chem 2006, 281:38519-38528.
106. Zhu J., Woods D., McMahon M., Bishop J.M. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev 1998, 12:2997-3007.
107. Lin A.W., Barradas M., Stone J.C., van Aelst L., Serrano M., Lowe S.W. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signalling. Genes Dev 1998, 12:3008-3019.
108. Katakura Y., Nakata E., Miura T., Shirahata S. Transforming growth factor beta triggers two independent-senescence programs in cancer cells. Biochem Biophys Res Commun 1999, 255:110-115.
109. Kortlever R.M., Higgins P.J., bernards R. Plasminogen activator inhibitor-1 is critical downstream target of p53 in the activation of replicative senescence. Nat Cell Biol 2006, 8:877-884.
110. Zhang H., Cohen S.N. Smurf2 up-regulation activates telomere-dependent senescence. Genes Dev 2004, 18:3028-3040.
111. Kim K.S., Kim M.S., Seu Y.B., Chung H.Y., Kim J.H., Kim J.R. Regulation of replicative senescence by insulin-like growth factor-binding protein 3 in human umbilical vein endothelial cells. Aging Cell 2007, 6:535-545.
112. Kim M.S., Seu Y.B., Baek S.H., Kim M.J., Kim K.J., Kim J.H., Kim J.R. Induction of cellular senescence by insulin-like growth factor binding protein-5 through a p53-dependent mechanism. Mol Biol Cell 2007, 18:4543-4552.
113. Pearson M., Carbone R., Sebastiani C., Cioce M., Fagioli M., Saito S., Higashimoto Y., Appella E., Minucci S., Pandolfi P.P., Pelicci P.G. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 2000, 406:207-210.
114. Denchi E.L., Attwooll C., Pasini D., Helin K. Deregulated E2F activity induces hyperplasia and senescence-like features in the mouse pituitary gland. Mol Cell Biol 2005, 25:2660-2672.
115. Grandori C., Wu K.J., Fernandez P., Ngouenet C., Grim J., Clurman B.E., Moser M.J., Oshima J., Russell D.W., Swisshelm K., et al. Werner syndrome protein limits Myc-induced cellular senescence. Genes Dev 2003, 17:1569-1574.
116. Collado M., Gil J., Efeyan A., Guerra C., Schuhmacher A.J., Barradas M., Benquria A., Zaballos A., Flores J.M., Barbacid M., et al. Tumor biology: senescence in premalignant tumours. Nature 2005, 436:642.
117. Dhomen N., Reis-Filho J.S., da Rocha Dias S., Hayward R., Savage K., Delmas V., Larue L., Pritchard C., Marais R. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 2009, 15:294-303.
118. Nardella C., Chen Z., Salmena L., Carracedo A., Alimonti A., Egia A., Carver B., Gerald W., Cordon-Cardo C., Pandolfi P.P. Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. Genes Dev 2008, 22:2172-2177.
119. Majumder P.K., Grisanzio C., O'Connell F., Barry M., Brito J.M., Xu Q., Guney I., Berger R., Herman P., Bikoff R., et al. A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell 2008, 14:146-155.
120. Wu C.H., Riggelen J., Yetil A., Fan A.C., Bachireddy P., Felsher D.W. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci U S A 2007, 104:13028-13033.
121. Soucek L., Whitfield J., Martins C.P., Finch A.J., Murphy D.J., Sodir N.M., Karnezis A.N., Swigart L.B., Nasi S., Evan G.I. Modeling Myc inhibition as a cancer therapy. Nature 2008, 455:679-683.
122. Qian Y., Zhang J., Yan B., Chen X. DEC1, a basic helix-loop-helix transcriptional factor and a novel target gene of the p53 family, mediates p53-dependent premature senescence. J Biol Chem 2008, 283:2896-2905.
123. Sansone P., Storci G., Tavolari S., Guarnieri C., Giovannini C., Taffurelli M., Ceccarelli C., Santitni D., Paterini P., Marcu K.B., et al. IL-6 triggers malignant features in mammospheres from human ductal carcinoma and normal mammary gland. J Clin Invest 2007, 117:3988-4002.
124. Coppé J.P., Kauser K., Campisi J., Beauséjour C.M. Secretion of vascular endothelial growth factor by primary human fibroblasts at senescence. J Biol Chem 2006, 281:29568-29574.
125. Tremain R., Marko M., Kinnimulki V., Ueno H., Bottinger E., Glick A. Defects in TGFβ signaling overcome senescence of mouse keratinocytes expressing v-rasHa. Oncogene 2000, 19:1609-1709.
126. Moiseeva O., Mallette F.A., Mukhopadhyay U.K., Moores A., Ferbeyre G. DNA damage signaling and p53-dependent senescence after prolonged beta-interferon stimulation. Mol Biol Cell 2006, 17:1583-1592.